TAKE Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹4 Cr
QMar 2026
In Mar 2026, TAKE (TAKE) reported revenue ₹59 Cr and net profit ₹4 Cr — revenue +2850.0% YoY. View TAKE 52-week performance for the annual high/low range and current price position.
TAKE Quarterly Results — Revenue, Profit & EPS Highlights
TAKE latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit TAKE screener.
- Revenue of ₹59 Cr in Mar 2026 (+84.4% vs Jun 2026, +2850.0% vs Mar 2025)
- Net Profit of ₹4 Cr in Mar 2026 (+300.0% vs Jun 2026, +180.0% vs Mar 2025)
- EBITDA of ₹4 Cr in Mar 2026 (+300.0% vs Jun 2026)
- Operating Margin of -2.0% in Mar 2026 (-1.0pp vs Jun 2026)
- Earnings Per Share of ₹0.29 in Mar 2026 (+314.3% vs Jun 2026)
TAKE Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TAKE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 59 | 32 | 7 | 2 | 0 | 84.4% | 2850.0% |
| Net Profit (₹ Cr) | 4 | 1 | 6 | -5 | -1 | - | - |
| EBITDA (₹ Cr) | 4 | 1 | 7 | -5 | -1 | - | - |
| EPS (₹) | 0.29 | 0.07 | 0.43 | -0.33 | -0.06 | - | - |
| Operating Margin (%) | -2.0% | -1.0% | 0.0% | 0.0% | 0.0% | - | - |
TAKE Share Price Trend — 1-Year Movement Across Quarterly Results
TAKE 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse TAKE ownership structure to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Mar 2025
2
Sept 2025
7
Jun 2026
32
Mar 2026
59
Net Profit Trend (₹ Cr)
Mar 2025
-5
Sept 2025
6
Jun 2026
1
Mar 2026
4
Operating Margin Trend (%)
Mar 2025
0.0%
Sept 2025
0.0%
Jun 2026
-1.0%
Mar 2026
-2.0%
TAKE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
TAKE latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores